Amphastar Pharmaceuticals, Inc. (AMPH)
NASDAQ: AMPH · Real-Time Price · USD
18.85
-0.45 (-2.33%)
May 29, 2026, 4:00 PM EDT - Market closed
Amphastar Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 720.53 | 719.89 | 731.97 | 644.4 | 498.99 | 437.77 | |
Revenue Growth (YoY) | -1.39% | -1.65% | 13.59% | 29.14% | 13.98% | 25.13% |
Cost of Revenue | 379.4 | 363.83 | 358.11 | 293.27 | 250.13 | 238.03 |
Gross Profit | 341.13 | 356.06 | 373.86 | 351.12 | 248.86 | 199.74 |
Selling, General & Admin | 131.9 | 129.81 | 94.52 | 80.39 | 66.59 | 68.92 |
Research & Development | 92.49 | 85.84 | 73.91 | 73.74 | 74.77 | 60.93 |
Total Operating Expenses | 224.39 | 215.65 | 168.44 | 154.13 | 141.36 | 129.85 |
Operating Income | 116.74 | 140.4 | 205.42 | 196.99 | 107.5 | 69.89 |
Interest Income | 8.99 | 8.68 | 10.61 | 5.46 | 1.32 | 0.6 |
Interest Expense | -25.75 | -25.48 | -30.34 | -27.16 | -1.85 | -0.89 |
Other Non-Operating Income (Expense) | 2.83 | 0.02 | 4.08 | -3.93 | 9.07 | 14.54 |
Total Non-Operating Income (Expense) | -13.93 | -16.78 | -15.66 | -25.63 | 8.54 | 14.25 |
Pretax Income | 102.81 | 123.62 | 189.76 | 171.36 | 116.04 | 84.14 |
Provision for Income Taxes | 23.59 | 25.53 | 29.67 | 31.83 | 23.48 | 20.63 |
Net Income | 72.81 | 98.09 | 159.52 | 137.55 | 91.39 | 64.49 |
Minority Interest in Earnings | - | - | 0.57 | 1.98 | 1.18 | -0.98 |
Net Income to Common | 72.81 | 98.09 | 159.52 | 137.55 | 91.39 | 64.49 |
Net Income Growth | -37.42% | -38.51% | 15.98% | 50.51% | 41.71% | 8052.46% |
Shares Outstanding (Basic) | 46 | 47 | 48 | 48 | 49 | 48 |
Shares Outstanding (Diluted) | 47 | 48 | 52 | 53 | 52 | 50 |
Shares Change (YoY) | -7.65% | -7.38% | -1.78% | 1.09% | 5.31% | 1.34% |
EPS (Basic) | 1.71 | 2.10 | 3.29 | 2.85 | 1.88 | 1.30 |
EPS (Diluted) | 1.66 | 2.03 | 3.06 | 2.60 | 1.74 | 1.25 |
EPS Growth | -39.86% | -33.66% | 17.69% | 49.43% | 39.20% | 4066.67% |
Shares Outstanding | 44.64 | 45.65 | 47.62 | 48.07 | 48.11 | 47.71 |
Free Cash Flow | 135.19 | 121.23 | 172.35 | 145.34 | 65.15 | 70.54 |
Free Cash Flow Growth | 11.51% | -29.66% | 18.58% | 123.09% | -7.64% | 201.30% |
Free Cash Flow Per Share | 2.85 | 2.51 | 3.31 | 2.74 | 1.24 | 1.42 |
Gross Margin | 47.34% | 49.46% | 51.08% | 54.49% | 49.87% | 45.63% |
Operating Margin | 16.20% | 19.50% | 28.06% | 30.57% | 21.54% | 15.96% |
Profit Margin | 10.10% | 13.63% | 21.87% | 21.65% | 18.55% | 14.51% |
FCF Margin | 18.76% | 16.84% | 23.55% | 22.55% | 13.06% | 16.11% |
EBITDA | 174.17 | 197.1 | 258.39 | 235.02 | 132.27 | 93.15 |
EBITDA Margin | 24.17% | 27.38% | 35.30% | 36.47% | 26.51% | 21.28% |
EBIT | 116.74 | 140.4 | 205.42 | 196.99 | 107.5 | 69.89 |
EBIT Margin | 16.20% | 19.50% | 28.06% | 30.57% | 21.54% | 15.96% |
Effective Tax Rate | 22.94% | 20.65% | 15.64% | 18.58% | 20.23% | 24.52% |